SCHEDULE: Deep Track Capital Discloses 9.74% Stake in MoonLake Immunotherapeutics

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 9.74% of MoonLake Immunotherapeutics' Class A ordinary shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G, indicating their beneficial ownership of MoonLake Immunotherapeutics' Class A ordinary shares.
• As of June 30, 2026, the reporting persons collectively beneficially own 7,999,025 shares, representing 9.74% of the class.
• This ownership includes 1,000,000 Pre-Funded Warrants exercisable into common shares, subject to a 9.99% ownership limitation.
• The filing states that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not overwhelming stake in the company. The disclosure itself is routine for institutional investors.

Positives

• Institutional investor Deep Track Capital has taken a significant stake (9.74%) in MoonLake Immunotherapeutics, which can signal confidence in the company's prospects.
• The inclusion of Pre-Funded Warrants suggests a strategic investment with potential for further equity acquisition.

Negatives

• The 9.99% ownership limitation on Pre-Funded Warrants caps the potential voting power and influence from these specific instruments.

Risks

• The 9.99% 'Maximum Percentage' limitation on exercising Pre-Funded Warrants could restrict the reporting persons' ability to increase their stake beyond this threshold without triggering specific conditions or limitations.
• Potential for future changes in beneficial ownership, as this is a snapshot in time and holdings can be adjusted.

Future Outlook

The filing does not contain forward-looking statements or specific future guidance from the company itself, but rather reports on current beneficial ownership.

Management Comments

• David Kroin, Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
• David Kroin, Director for Deep Track Biotechnology Master Fund, Ltd., provided similar certification.
• David Kroin certified that the information in the statement is true, complete, and correct.

Industry Context

StockSavvy.ai notes that significant stake disclosures by institutional investors like Deep Track Capital are common in the biotechnology sector, reflecting active portfolio management and strategic investment in companies with promising pipelines or technologies.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may be viewed positively, potentially indicating increased institutional interest and stability.
• Management: The filing confirms that the investment is not intended to influence control, which may be reassuring to current management.

Next Steps

• The reporting persons will continue to monitor their investment in MoonLake Immunotherapeutics.
• Future amendments to the Schedule 13G will be filed if there are material changes in beneficial ownership.

Key Dates

Keywords

MoonLake Immunotherapeutics, Deep Track Capital, Schedule 13G, Beneficial Ownership, Class A ordinary share, Pre-Funded Warrants, Institutional Investor, Biotechnology